NASDAQ · Biotechnology

ZURA (ZURA) Stock

$5.64 -0.88% NASDAQ: ZURA Healthcare

Valuation

MetricValue
Price$5.64
Market Cap$535.79M
P/E Ratio-3.76
P/B Ratio2.54
P/S Ratio0.00
EPS (TTM)$-1.06
52-Week High$7.44
52-Week Low$1.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-67.65%
ROA-60.53%
ROCE-73.53%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio9.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-27.0M$-63.0M$-55.0M$-75.0M
Net Profit$8.0M$-26.0M$-60.0M$-52.0M$-69.0M
EPS$0.40$0.21$-2.09$-0.60$-1.06
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$141.0M$5.0M$101.0M$180.0M$114.0M
Total Liabilities$10.0M$27.0M$21.0M$20.0M$12.0M
Cash$1.0M$2.0M$100.0M$176.0M$109.0M
Borrowings$0$8.0M$0$0$0

Latest News

William Blair Starts Zura Bio (ZURA) at Outperform Insider Monkey · Jul 14, 2026 William Blair Initiates Zura Bio at Outperform MT Newswires · Jul 8, 2026 Tenaya Therapeutics Names Eric Hyllengren CFO MT Newswires · Jun 29, 2026 Zura Bio Exceeds Enrollment Targets for Phase 2 Trials in Hidradenitis Suppurativa, Systemic Sclerosis MT Newswires · Jun 29, 2026 Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program Business Wire · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-1.0M$-15.0M$-28.0M$-65.0M
Investing Cash Flow$-139.0M$-24.0M$-16.0M$-5.0M$0
Financing Cash Flow$1.0M$-3.0M$15.0M$49.0M$-7.0M
Net Cash Flow$1.0M$2.0M$98.0M$77.0M$-67.0M
Free Cash Flow$-1.0M$-13.0M$-23.0M$-28.0M$-65.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-27.16%
Quick Ratio19.33
Interest Coverage—
Return 1Y213.02%
Return 3Y-21.86%
Return 5Y—

Ownership

Insiders Held21.51%
Institutions Held79.05%
Institutions Float Held100.72%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC9,067,0012026-03-31
Venrock Adviser, LLC6,434,9902026-03-31
JPMORGAN CHASE & CO4,458,8512026-03-31
Great Point Partners LLC4,215,9302026-03-31
Braidwell LP 3,988,9892026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AARD $6.42 -4.04% -1.62 $140.50M 0.00%
ARCT $6.26 +0.64% -2.93 $177.93M 0.00%
ASMB $26.68 +0.87% -51.53 $424.02M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%
FHTXFoghorn Therapeutics Inc. $5.20 +7.22% -4.15 $305.31M 0.00%

About ZURA

ZURA is led by CEO Sandeep C. Kulkarni, employs 30 people, headquartered in US, publicly traded since 2023.

ZURA stock trades at $5.64 with a market capitalization of $535.79M. The stock is valued at a price-to-earnings (P/E) ratio of -3.76, price-to-book of 2.54, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.00 and $7.44, and currently trades 24.2% below its 52-week high.

On profitability, ZURA generates a return on equity (ROE) of -67.65%, return on capital employed of -73.53%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides